Wrong....
“the Visolis Transaction which closed in October 2018 was an en-bloc purchase of assets of the three entities comprising the Company. This transaction did not include certain assets, which the Company (with the assistance of the Monitor) has subsequently sought to realize.”
“
32. The Company retained some of its contractual rights following the Visolis Transaction, as the purchaser did not force the assignment of contracts of the Company as part of that transaction. Notably, this includes the Company’s rights under certain development and licensing agreements with Cargill Incorporated (“Cargill”), as well as non-assertion agreements with Reverdia V.O.F. (“Reverdia”) and Mitsubishi Chemical Corporation (“MCC”) that permit the use of certain intellectual property by BioAmber Inc. The Monitor is exploring options to realize value from these rights of BioAmber Inc., but cautions that the ability to do so is subject to reaching agreement with Cargill, Reverdia and MCC on an acceptable acquirer, and on the satisfaction of material cure costs connected with those agreements.”
Market Data 
Markets 
